Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis

• Wai-kit Ming,
• Xiaoting Huang,
• Xiuhua Weng,
• Shen Lin,
• Yiwei Liu,
• Shaohong Luo,
• Hang Wang,
• Pinfang Huang

Affiliations

Wai-kit Ming

Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China

Xiaoting Huang

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Xiuhua Weng

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Shen Lin

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Yiwei Liu

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Shaohong Luo

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Hang Wang

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Pinfang Huang

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China